Davida Marie Gable, who serves as vice president and corporate controller, finance at Ingredion Inc (NYSE: INGR), executed a sale of 375 shares of the company's common stock on March 18, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The shares changed hands at $112.435 per share, producing a total transaction value of $42,163. After the disposition, Gable directly holds 7,110.142 shares of Ingredion common stock, as reported in the filing.
The sale took place while the stock trades at a price-to-earnings ratio of 9.86. InvestingPro analysis, cited in available company material, indicates that Ingredion is trading below its Fair Value estimate.
Ingredion's record of shareholder returns and cash distribution is also noted. According to InvestingPro Tips referenced by the company materials, Ingredion has paid dividends for 29 consecutive years and currently yields 2.95% on a trailing basis.
Separately, the company announced a $0.82 quarterly dividend per share that will be payable on April 21, 2026, to shareholders of record as of April 1, 2026.
Recent corporate initiatives and commercial arrangements were disclosed alongside the transaction. Ingredion has entered a research and development collaboration with Shiru to develop functional proteins, leveraging Shiru's AI discovery platform. In the commercial supply chain for pharmaceutical excipients, Univar Solutions LLC has been appointed as the exclusive distributor for Ingredion Pharma Solutions' pharmaceutical starches in the U.S. and Canada.
Executives also reorganized governance roles. James P. Zallie, previously the company's president and chief executive officer, has been appointed chairman of the board. Victoria J. Reich has been named lead director.
On the analyst front, BMO Capital Markets lowered its price target for Ingredion to $120 from $123 while maintaining a Market Perform rating. The firm cited the company's fourth-quarter earnings per share of $2.53, which missed the consensus estimate of $2.60. The earnings shortfall was attributed to weaker profitability in the Texturants and Hydrocolloids Solutions segment, and softness in the Food and Industrial segment in the U.S. and Canada.
For investors seeking expanded analysis, a comprehensive Pro Research Report is available for INGR and more than 1,400 other U.S. equities. The report is offered through InvestingPro and is presented as a tool to convert financial data into actionable insight.
All factual details in this report are drawn from the company's Form 4 filing and accompanying corporate disclosures. Where third-party analysis is mentioned, it reflects the evaluations as stated in the referenced materials.